Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 13/20 | 0.57 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 0.52 |
| ▸ | TNKS | O95271 | 12/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 12/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.44 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8201209 | 0.85 | PARP1 (0.56) | PARP1PARP2TNKSTNKS2KDM4E | |
| SCHEMBL8198835 | 0.76 | PARP1 (0.55) | PARP1PARP2TNKSTNKS2PARP14 | |
| SCHEMBL17829612 | 0.74 | PARP1 (0.70) | PARP1PARP2TNKSTNKS2PARP14 | |
| SCHEMBL4313736 | 0.74 | PARP1 (0.70) | PARP1PARP2TNKSTNKS2 | |
| SCHEMBL1387263 | 0.74 | PARP1 (1.00) | PARP1PARP2TNKSTNKS2KDM4E | |
| SCHEMBL21072769 | 0.71 | PARP1 (0.70) | PARP1PARP2TNKSTNKS2PARP14 | |
| SCHEMBL9671521 | 0.71 | PARP1 (0.70) | PARP1PARP2TNKSTNKS2PARP14 | |
| SCHEMBL164147 | 0.71 | TNKS (0.54) | PARP1PARP2TNKSTNKS2PARP14 | |
| SCHEMBL6929158 | 0.71 | PARP1 (0.64) | PARP1PARP2TNKSTNKS2PARP14 | |
| SCHEMBL31483817 | 0.71 | PARP1 (0.64) | PARP1PARP2TNKSTNKS2PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | FOS, FOSB, YAP1 | PARP1 2477/4885PARP2 3602/4885TNKS 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.